HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.49B
Enterprise Value 32.16B
Trailing P/E -19.16
Forward P/E 1-22.43
PEG Ratio (5 yr expected) 1-2.50
Price/Sales (ttm)18.57
Price/Book (mrq)40.83
Enterprise Value/Revenue 316.11
Enterprise Value/EBITDA 6-22.56

Financial Highlights

Fiscal Year
Fiscal Year Ends Dec 31, 2016
Most Recent Quarter (mrq)Jun 30, 2017
Profit Margin -89.43%
Operating Margin (ttm)-73.28%
Management Effectiveness
Return on Assets (ttm)-19.18%
Return on Equity (ttm)-352.48%
Income Statement
Revenue (ttm)134.17M
Revenue Per Share (ttm)1.03
Quarterly Revenue Growth (yoy)1.20%
Gross Profit (ttm)113.48M
EBITDA -95.85M
Net Income Avi to Common (ttm)-119.99M
Diluted EPS (ttm)-0.93
Quarterly Earnings Growth (yoy)N/A
Balance Sheet
Total Cash (mrq)297.53M
Total Cash Per Share (mrq)2.22
Total Debt (mrq)211.03M
Total Debt/Equity (mrq)362.82
Current Ratio (mrq)4.13
Book Value Per Share (mrq)0.43
Cash Flow Statement
Operating Cash Flow (ttm)-63.97M
Levered Free Cash Flow (ttm)-32.37M

Trading Information

Stock Price History
Beta 2.59
52-Week Change 384.79%
S&P500 52-Week Change 319.52%
52 Week High 318.43
52 Week Low 38.18
50-Day Moving Average 315.93
200-Day Moving Average 313.82
Share Statistics
Avg Vol (3 month) 31.26M
Avg Vol (10 day) 31.14M
Shares Outstanding 5140.62M
Float 118.94M
% Held by Insiders 10.97%
% Held by Institutions 186.31%
Shares Short 321.36M
Short Ratio 333.39
Short % of Float 323.47%
Shares Short (prior month) 321.13M
Dividends & Splits
Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A